HumacyteHUMA
HUMA
About: Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.
Employees: 220
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
84% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 25
33% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 39
13% more funds holding
Funds holding: 143 [Q3] → 162 (+19) [Q4]
9% more capital invested
Capital invested by funds: $195M [Q3] → $213M (+$18M) [Q4]
2.76% more ownership
Funds ownership: 29.94% [Q3] → 32.71% (+2.76%) [Q4]
44% less call options, than puts
Call options by funds: $4.41M | Put options by funds: $7.9M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
934%
upside
Avg. target
$20
1,279%
upside
High target
$25
1,624%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 28% 1-year accuracy 107 / 376 met price target | 1,624%upside $25 | Buy Maintained | 31 Mar 2025 |
HC Wainwright & Co. Vernon Bernardino 27% 1-year accuracy 19 / 70 met price target | 934%upside $15 | Buy Reiterated | 12 Mar 2025 |
Financial journalist opinion
Based on 4 articles about HUMA published over the past 30 days
Positive
Zacks Investment Research
7 hours ago
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
The latest trading day saw Humacyte, Inc. (HUMA) settling at $1.45, representing a +1.4% change from its previous close.
Positive
Zacks Investment Research
13 hours ago
All You Need to Know About Humacyte, Inc. (HUMA) Rating Upgrade to Buy
Humacyte, Inc. (HUMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
Zacks Investment Research
6 days ago
Humacyte, Inc. (HUMA) Ascends But Remains Behind Market: Some Facts to Note
Humacyte, Inc. (HUMA) reachead $1.48 at the closing of the latest trading day, reflecting a +0.68% change compared to its last close.
Negative
Zacks Investment Research
2 weeks ago
Humacyte, Inc. (HUMA) Increases Despite Market Slip: Here's What You Need to Know
Humacyte, Inc. (HUMA) reachead $1.55 at the closing of the latest trading day, reflecting a +0.65% change compared to its last close.
Neutral
Seeking Alpha
1 month ago
Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript
Humacyte, Inc. (NASDAQ:HUMA ) Q4 2024 Earnings Conference Call March 27, 2025 8:30 AM ET Company Participants Thomas Johnson - Director, Corporate Communications, LifeSci Advisors, IR Laura Niklason - President and CEO Dale Sander - CFO and Chief Corporate Development Officer Conference Call Participants Josh Jennings - TD Cowen & Company Ryan Zimmerman - BTIG Vernon Bernardino - H.C. Wainwright Bruce Jackson - Benchmark Company Operator Good morning, ladies and gentlemen.
Neutral
GlobeNewsWire
1 month ago
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
- Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma -
Negative
Zacks Investment Research
1 month ago
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Neutral
GlobeNewsWire
1 month ago
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025
DURHAM, N.C., March 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the fourth quarter and year ended December 31, 2024, on Friday, March 28, 2025.
Neutral
GlobeNewsWire
1 month ago
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 25,000,000 shares of its common stock at a public offering price of $2.00 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about March 27, 2025, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 3,750,000 shares of Humacyte's common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.
Neutral
GlobeNewsWire
1 month ago
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has commenced an underwritten public offering of its common stock. In addition, Humacyte intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. All of the shares are being offered by Humacyte.
Charts implemented using Lightweight Charts™